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ROSLeber hereditary optic neuropathy (LHON), acute or subacute vision loss due to retinal ganglion cell death
which in the long run leads to optic nerve atrophy is one of the most widely studied maternally inherited
diseases caused by mutations in mitochondrial DNA. Although three common mutations, 11778GNA,
14484TNC or 3460GNA are responsible for over 90% of cases and affect genes encoding complex I subunits of
the respiratory chain, their inﬂuence on bioenergetic properties of the cell is marginal and cannot fully
explain the pathology of the disease. The following chain of events was proposed, based on biochemical and
anatomical properties of retinal ganglion cells whose axons form the optic nerve: mitochondrial DNA
mutations increase reactive oxygen species production in these sensitive cells, leading to caspase-
independent apoptosis. As LHON is characterized by low penetrance and sex bias (men are affected about
5 times more frequently than women) the participation of the other factors—genetic and environmental—
beside mtDNA mutations was studied. Mitochondrial haplogroups and smoking are some of the factors
involved in the complex etiology of this disease.technology, Faculty of Biology,
aw, Poland.
.
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Mitochondrial diseases are disorders affecting the oxidative
phosphorylation system. They may be caused by mutations in nuclear
as well as mitochondrial DNA. Mitochondrial DNA is a circular
molecule encoding 13 respiratory chain proteins, 22 tRNA and 2 rRNA
molecules, and is highly compact with no introns and virtually no
noncoding regions except for the regulatory one called the D-loop.
mtDNA is present in the cell in numerous copies, up to several
thousand in some types of cells, and is maternally inherited [1].
Mitochondrial diseases caused bymutations in mitochondrial DNA
are generally considered as neuromuscular or even multisystem
disorders. This is true for most of them, the most frequent one,
affecting about 1 in 20 000 inhabitants in some regions of Europe [2].
Leber hereditary optic neuropathy (LHON) in its typical form is the
isolated atrophy of the optic nerve. It occurs mostly in young adults
affecting both eyes simultaneously or sequentially over a period of
several weeks or months and is associated with painless, acute or
subacute vision loss. The severity differs between patients, even
between members of the same family: sometimes light perception
can be retained and partial vision recovery, even after several years,
occurs in some cases [3].
In over 90% of cases, LHON is caused by one of three mitochondrial
DNA (mtDNA) missense mutations in genes encoding subunits ofNADH dehydrogenase (ND): 11778GNA (ND4), 14484TNC (ND6) or
3460GNA (ND1) [4]. They are commonly present in the organism in a
homoplasmic state (all mtDNA molecules have the mutation), but
heteroplasmic (mutated and unmutated mtDNA molecules present)
cases are also known. The most severe known mutation is 14459GNA,
which shows a wide clinical variability mostly causing a LHON plus
phenotype (additional neurological features accompanying typical
atrophy of the optic nerve) [5] however patients presenting only with
classical LHON are also observed. 14459GNA cannot be easily
compared to the three above-mentioned common mutations.
3460GNA mutation is considered to be severe, 11778GNA—interme-
diate, whereas 14484TNC is rather mild [6]. A minority of cases are
attributed to other mtDNA mutations mostly in ND genes. Some of
them have been observed in several independent families, but there is
a large number of potentially pathogenic mutations still needing
conﬁrmation [7–9]. The penetrance is low, up to 50% in men and 10%
in women. To make things more complicated, the involvement and
role of additional genetic factors (like mitochondrial DNA variants) as
the modiﬁers of disease expression is widely disputed [10].
Although in majority of cases LHON mutations lead to isolated
optic nerve atrophy, a small group of LHON plus patients exhibit
various neurological symptoms like cerebellar ataxia or psychomotor
regression with MRI changes and other abnormalities typical for
mitochondrial encephalomyopathies of progressive character [11,12].
On the other hand, in a large population of asymptomatic carriers
studies of color discrimination have shown color vision loss in men,
especially for green and red, which is also typical for patients with
fully developed LHON [13].
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presymptomatic phase characterized by peripapillary microangio-
pathy with tortuous vessels, which can last for many years and can
even be lifelong. In the acute phase, peripapillary teleangiectatic
microangiopathy and swelling of retinal nerve ﬁber layer around the
optic disc along with loss of the papillomacular bundle, starting with
more sensitive smaller ﬁbers, is observed. After about 6 months, the
vision loss usually stabilizes, the optic nerve atrophy is evident and
patients enter the chronic phase of the disease. Optical coherence
tomography, a noninvasive imaging technique allowing real-time
examination of the retina and optic nerve, revealed that the thickness
of the retinal nerve ﬁber layer (RNLF) correlates with the clinical state
of the patient, being slightly thicker in unaffected carriers and in
subclinical phase in the temporal quadrant, thicker in the acute phase
and getting thinner in the chronic phase. Thinning starts again from
the temporal quadrant. Similar thinning of RNLF, predominantly in
the temporal quadrant, is observed in autosomal dominant optic
atrophy patients (ADOA) with mutations in the OPA1 gene [14–18].
In most of the cases, vision loss is permanent, although spontane-
ous recovery is sometimes observed. The frequency of visual recovery
depends on the type of mutation, being most frequent for the
14484TNC, and on the age of onset—young patients and children,
very rarely affected with LHON, have a higher chance of sight
improvement [19].
Besides the limited phenotypic effects of the disease, where only
the optic nerve is affected, there is one more striking and very
characteristic feature of this particular disorder not observed in other
mitochondrial diseases: the higher incidence in men. In the literature
male to female ratios vary between about 2:1 and almost 8:1 [20]
depending on the type of mutation. The ratios calculated from an
extensive LHON study by Hudson et al. [6] are about 4:1 for 11778GNA,
6.4:1 for 14484TNC and 2.3:1 for 3460GNA mutation. The basis of this
phenomenon is still unknown and an additional X-linked factor has
been postulated in several studies but no gene has been found [21–23].
Although LHON is one of the best studied mitochondrial disorders,
the exact mechanism of pathology is still not fully known. Since the
mitochondrion is the power factory of the cell, the most obvious
explanation was that the mtDNA defect leads to a signiﬁcant decrease
in energy production and failure in optic nerve function. As the
experimental data were confusing and the rather small decrease in
energy production for some mutations could not explain all the
observed phenotypic effects, alternative explanations such as in-
creased oxidative stress, apoptosis and altered axonal transport of the
organelles have been proposed [24].2. Energetic failure?
One of the greatest complications in studying biochemistry and
physiology of LHON is the fact that the only affected tissues are retinal
ganglion cells (RGC) and the optic nerve, which are not easily
accessible for in vitro studies, while the mutations are present in the
whole body at a very high, even homoplasmic level, giving no clinical
phenotype.
For molecular as well as biochemical studies, numerous cellular
models have been used: ﬁbroblasts, platelets, lymphoblasts or skeletal
muscle [25], but the most consistent results were obtained with
cytoplasmic hybrids (called cybrids) commonly used for mitochon-
drial mutation research. Cybrids are derived from the fusion of cells
deprived of mitochondrial DNA by long culture on ethidium bromide
(called Rho0 cells) and cytoplasts—enucleated cells containing the
analyzed mitochondria originating from the patient's cells (blood
platelets, as structures which naturally do not have nuclei, but having
mitochondria, can replace the cytoplasts in this method). The
resulting cells have nuclei from Rho0 cells, but mitochondria from
the patient and allow for analysis and comparison of the effect ofdifferent mitochondrial DNA variants in the same nuclear background
[26].
The respiratory capacity and complex I activity were tested in
cybrids and the lymphoblast cell lines bearing all three most common
LHON mutations, 11778GNA, 14484TNC or 3460GNA. 3460GNA and
11778GNA mutations indeed showed a decrease in respiration rate as
well as in complex I activity (especially the former was reduced by
about 70% in enzymatic assays in 3460GNA cybrids and even more in
lymphoblasts), which is consistent with the fact that it is one of the
most deleterious LHONmutations. For 11778GNA respiration rate was
only moderately but signiﬁcantly lowered in both cell types but
enzymatic complex I activity was altered only in lymphoblasts. No
such effect was observed for the mild mutation 14484TNC, where the
respiration rate was lowered by about 10–15% in lymphoblasts only
with no change in complex I activity [25]. Although these data reﬂect
the connection between the severity of the mutation and the severity
of the OXPHOS defect, they cannot explain the pathomechanism of
the disease, especially in case of the 14484TNC mutation [25].
A possible explanation was that mitochondria function differently
in neuronal cells. Since it is impossible to study affected neurons,
cybrids were again used, but this time 3460GNA and 11778GNA
mutations were placed in the context of neural NT2 cells [27]. Again
the results were not unequivocal. No reduction in membrane
potential was observed in both differentiated and undifferentiated
states, but the differentiation process appeared to be altered for LHON
mutation bearing cells, since the yield of obtained differentiated cells
was decreased.
As these studies gave only little support for the bioenergetic theory
of LHON pathology, another possible mechanism was suggested.
3. Reactive oxygen species production?
Mitochondria are the biggest reactive oxygen species (ROS)
factory in the cell, and ROS may damage the cell via numerous
mechanisms. As dysfunction in the respiratory chain can lead to
elevated ROS production, the mechanism of LHONmutation inﬂuence
on cell physiology became an attractive hypothesis [28].
Indeed, the above-mentioned neuronal cybrids revealed that ROS
production was increased about 2.5-fold in cells bearing all three
common LHON mutations, but the effect was observed only in
differentiated cells, and was absent in undifferentiated ones with the
samemutations [27]. As LHON is mostly a defect in complex I genes, it
is worth mentioning that inhibition of complex I by rotenone leads to
oxygen radical overproduction in human skin ﬁbroblasts, to increased
complexity of mitochondrial reticulum and to general outgrowth of
mitochondria, which may be a compensatory effect [29,30].
At the same time, higher concentrations of rotenone cause
apoptotic death of the cells with all the typical hallmarks like DNA
laddering, cytochrome c release, or activation of caspase 3 by elevated
ROS production, although the extent of the phenomenon was
dependent on the cell type [30].
4. Apoptosis?
The next obvious question is whether apoptosis is involved in the
atrophy of the optic nerve in LHON. There is no straightforwardway to
answer it. Even limited post-mortem analysis of the optic nervewould
not give clues, because neuron degeneration would have occurred
many years earlier [31]. Indirect evidence comes from the fact that
there are no signs of inﬂammation in the optic nerve [32].
Are the cells harboring mtDNA Leber mutations more prone to
apoptotic cell death? In the very well characterized apoptotic
pathway, mitochondria play a central role in amplifying the apoptotic
signal, thus apoptosis of cells containing mitochondria with these
mutations would be a very reasonable explanation of LHON
pathology. There is increasing support for this hypothesis. Cybrids
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sensitive to apoptotic death after treatment with anti-Fas receptor
antibodies [32]. A similar effect was observed in the culture of the
cybrids on non-fermentable energy sources like galactose. Cell lines
with each of the three typical LHONmutations died within a few days,
showing nuclear morphology typical for apoptosis as well as DNA
fragmentation and cytochrome c release—signs of mitochondrial
involvement in the process. However, caspase-3 activation was not
observed [33]. More detailed studies revealed that the culture on
galactose resulted in a signiﬁcant reduction in ATP production and
apoptotic death via a caspase-independent pathway with the
sequential release of cytochrome c, AIF and EndoG frommitochondria
[34,35].
5. Why the optic, but not any other nerve?
The answer to this fundamental question can lie in the complex
structure formed by retinal ganglion cells whose axons constitute the
optic nerve. The 5 cm long axons turn at a right angle while leaving
the eye and entering the head of the optic nerve, then cross the lamina
cribrosa [36]. The paths taken by individual axons may vary,
depending on the place in which they start. Another interesting
morphological feature is myelination: it is present in the part of the
nerve located behind the lamina, while it is absent in the head of the
optic nerve. The mitochondrial content is higher in the unmyelinated
part, reﬂecting the higher energetic requirements needed to sustain
the action potential. In such a complicated structure, some of its parts
may be more prone to different damaging factors [36].
Unlike any other part of the nervous system, the retina is exposed
to light, which can be responsible for increased ROS production. As
ROS production is already increased in cells with LHON mutations,
additional light-induced ROS production may lead to the damage of
very sensitive Muller glial cells, which are responsible for mainte-
nance of RGC homeostasis [37].
Another characteristic of the RGC cells is that they are sensitive to
glutamate levels and die when the expression of excitatory amino acid
transporter EAAT1 responsible for glutamate uptake is low. At the
same time LHON mutations are known to inﬂuence the function of
this transporter in cybrid models and cells with these mutations show
decreased glutamate levels [37–39].
Comparison of LHON with another genetic disorder affecting the
same type of cells—Autosomal Dominant Optic Atrophy frequently
caused by mutations in the OPA1 gene encoding a protein similar to
dynamins and responsible for proper mitochondrial cristae formation—
is very interesting. Mutations in OPA1, although via different mechan-
isms, lead toOXPHOSdefect anduncoupling of the respiratory chain and
cause the release of cytochrome c and apoptosis. Similar effects
obtained through different mechanisms may be an indication of the
susceptibility of optic nerve cells to apoptosis, resulting from
different factors [40,41].
6. Modifying factors
Reduced penetrance, a highmale to female ratio, and the existence
of LHON plus cases strongly suggest the involvement of modifying
factors—genetic or environmental.
6.1. Genetic factors
The ﬁrst factor frequently suggested as a genetic modiﬁer is the
mitochondrial haplogroup. A haplogroup is the collection of poly-
morphisms forming a haplotype reﬂecting the evolutionary history of
the mtDNA molecule. Most of the Caucasian mtDNAs belong to, in
order of frequency, haplogroups H, U, T, J, K, V, W, X, I and M [42].
Population studies revealed that a very high frequency of haplogroup J
is observed in LHON patients with the 14484TNC mutation. A founderevent has explained this effect in at least two populations: French–
Canadian and Dutch [43,44], but was excluded in Italian 14484TNC
carriers. A slightly higher frequency of haplogroup J has also been
observed for patients with the 11778GNA mutation, which may
suggest that it has a negative inﬂuence on the LHON phenotype [45].
Detailed studies and statistical analysis revealed the association of
11778GNA mutation with J2b and J1c subhaplogroups characterized
by additional non-synonymous changes in Cytb mitochondrial gene
and higher penetrance in the J2 subhaplogroup. For 14484TNC
mutation, higher incidence and increased penetrance in subha-
plogroup J1 versus J2 were observed, while only 1% of cases belonged
to a haplogroup other than J. For 3460GNA, the increased risk was
associated with haplogroup K, which bears another non-synonymous
variant of Cytb [6,25].
At the same time, it was observed that in some populations
haplogroup J is more frequent in elderly people [46] and can have a
protective effect against Parkinson disease [47]. The above observa-
tions have led to a hypothesis that the region speciﬁc variants
forming haplogroups show different bioenergetic properties helping
their owners to adapt to the environment in which they are living,
while at the same time making them prone to different disorders,
which also demonstrate geographic speciﬁcity. Wallace [48] has
proposed that haplogroup-speciﬁc polymorphisms, including those
found in haplogroup J, contribute to more uncoupled mitochondria. If
this is indeed true, it could help explain why persons with
haplogroup J are more susceptible to LHON, while they are more
likely to age well.
At the molecular level, haplogroup J D-loop polymorphisms may
inﬂuence transcription and replication of mtDNA [49]. At the same
time, the bearers of another European haplogroup, haplogroup H,
seem to have decreased risk of developing LHON [6]. Altogether the
inﬂuence of the haplogroup on the phenotype may be quite complex
in LHON.
In rare situations two mtDNA LHON mutations occur in the same
patient. Only 5 such families have been described: 4 with a
combination of 11778GNA and 14484TNC and one with 3460GNA
and 11778GNA mutations. Although the presence of two mutations
would have been expected to result in a more severe phenotype it
only seemed to positively inﬂuence penetrance and the LHON plus
phenotype was observed only in one family with the 11778GNA and
14484TNC mutations. This lack of aggravation of the phenotype by
two mutations in subunits of the same mitochondrial complex may
indicate that even though the mutations differ in severity, they affect
exactly the same process in mitochondria [50–53]. Even the family
bearing the two severe mutations 3460GNA and 11778GNA did not
have any additional symptoms other than LHON [53].
Because of the imbalance in male to female LHON cases, an X-
linked factor was sought. Until now no such modiﬁer gene has been
found, but several susceptibility regions have been described, which
may suggest the genetic variability of X-linked factors [21–23,54,55].6.2. Environmental factors
Since known genetic inﬂuences cannot explain low penetrance, a
search for environmental factors was initiated. The best studied ones
are cigarette smoking and alcohol consumption. For a very long time
conﬂicting sets of data existed; some showing the negative inﬂuence
of tobacco smoking or alcohol on onset or progress of the disease, and
some stating they had no effect [56,57].
Recent extensive analysis of more than 400 affected and
unaffected LHON carriers revealed that smoking is associated with a
higher risk of developing symptomatic disease, and that heavy
smokers were more susceptible to it. The effect of alcohol on disease
development was not as strong and did not reach statistical
signiﬁcance [58].
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trauma: physical injury, psychological stress, infection or exposure to
toxic factors. This phenomenon is also observed for other mitochon-
drial diseases and is another proof for interaction between genes and
the environment [58–60].
7. In search of therapy
At present there is no causal treatment of mitochondrial diseases,
and in the case of Leber hereditary optic neuropathy there is no
symptomatic one. Clinicians generally advise patients not to smoke or
drink alcohol. Some of the patients receive anti-inﬂammatory drugs,
with no positive effect, often before the ﬁnal diagnosis is made.
Attempts to ﬁnd an active factor improving vision in LHON
patients are made on the cell culture level as well as in patients and
one of the drugs is now in clinical trial phase. The most widely used
component is Coenzyme Q10 and its synthetic analogue idebenone as
both are effective antioxidants used to reduce reactive oxygen species
level contributing to the pathology of the disease. Currently a double
blind, randomized placebo controlled clinical phase II trial of
idebenone is in progress.
Retrospective studies of idebenone and vitamin (vitamin B2 and
vitamin C) treatment suggest that although the number of cases of
visual recovery has not changed, the interval between the onset of
LHON and the beginning of the recovery process was shortened,
which was statistically signiﬁcant. This treatment may be much more
effective in preventing the loss of vision in mutation carriers than in
actually curing the disease [9,61,62].
There is a potential ﬁeld for utilizing some other antioxidants,
apoptosis inhibiting factors, or a wide variety of different neuropro-
tective agents which were found to improve the function of RGC cells
in different models.
A combination of all clinical, biochemical, physiological and
molecular data clearly show that, while mitochondrial DNAmutations
are essential for disease development, they are far from being the only
cause. The interaction of different genetic and environmental factors
is responsible for the expression of this highly variable and still
mysterious disorder, placing it among multifactorial rather than
strictly mitochondrial diseases.
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